On Monday, Fennec Pharmaceuticals Inc. (FENC) announced the appointment of Jeffrey Hackman as Chief Executive Officer and Board member, effective August 16, 2024.
Rosty Raykov, who has served as CEO since 2009, will continue his role on the Board.
The company stated that Hackman's appointment aims to advance the development of PEDMARK, the only approved treatment in the United States designed to reduce the risk of cisplatin-induced ototoxicity in pediatric cancer patients.
Hackman brings over 30 years of experience in commercial leadership, including 12 years focused on oncology. He has successfully led over 10 product launches and has brought products to market pertinent to PEDMARK's objectives.
